Lachelle Dawn Weeks, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uracil-DNA Glycosidase | 3 | 2014 | 35 | 0.990 |
Why?
|
Guanine | 3 | 2014 | 278 | 0.900 |
Why?
|
Glutamates | 3 | 2014 | 385 | 0.890 |
Why?
|
Hematology | 2 | 2022 | 243 | 0.760 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2022 | 92 | 0.740 |
Why?
|
Precancerous Conditions | 1 | 2023 | 982 | 0.550 |
Why?
|
Burnout, Professional | 2 | 2023 | 703 | 0.540 |
Why?
|
DNA Breaks, Double-Stranded | 3 | 2016 | 612 | 0.420 |
Why?
|
Hematologic Neoplasms | 1 | 2023 | 1895 | 0.390 |
Why?
|
Myelodysplastic Syndromes | 1 | 2022 | 1393 | 0.390 |
Why?
|
Dioxygenases | 2 | 2024 | 345 | 0.360 |
Why?
|
Hematopoietic Stem Cells | 1 | 2022 | 3388 | 0.330 |
Why?
|
Mutation | 6 | 2024 | 30006 | 0.250 |
Why?
|
Thrombocytosis | 1 | 2024 | 88 | 0.230 |
Why?
|
Thrombocythemia, Essential | 1 | 2024 | 113 | 0.220 |
Why?
|
Giant Cell Arteritis | 1 | 2024 | 307 | 0.170 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 382 | 0.160 |
Why?
|
Hydroxylamines | 2 | 2016 | 39 | 0.160 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2013 | 5300 | 0.150 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 240 | 0.150 |
Why?
|
Hematopoiesis | 2 | 2023 | 2046 | 0.140 |
Why?
|
Paraproteinemias | 1 | 2019 | 250 | 0.130 |
Why?
|
DNA Repair | 3 | 2016 | 2041 | 0.130 |
Why?
|
Teaching Rounds | 1 | 2020 | 276 | 0.130 |
Why?
|
Uracil | 2 | 2014 | 207 | 0.120 |
Why?
|
Gout | 1 | 2022 | 621 | 0.120 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 1549 | 0.120 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2016 | 349 | 0.120 |
Why?
|
Heart Arrest | 1 | 2024 | 1514 | 0.110 |
Why?
|
Lymphoma | 1 | 2023 | 1898 | 0.110 |
Why?
|
Education, Medical, Graduate | 2 | 2022 | 2372 | 0.100 |
Why?
|
Hemorrhage | 1 | 2024 | 3422 | 0.100 |
Why?
|
Patient Admission | 1 | 2019 | 1365 | 0.100 |
Why?
|
Cell Line, Tumor | 4 | 2016 | 16947 | 0.090 |
Why?
|
Medical Oncology | 1 | 2022 | 2316 | 0.090 |
Why?
|
Lung Neoplasms | 2 | 2016 | 13382 | 0.080 |
Why?
|
Cell Cycle | 2 | 2016 | 2926 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2757 | 0.080 |
Why?
|
Cytokines | 1 | 2023 | 7386 | 0.080 |
Why?
|
Humans | 22 | 2024 | 761098 | 0.080 |
Why?
|
Heart Failure | 2 | 2024 | 11701 | 0.070 |
Why?
|
Cardiovascular Diseases | 2 | 2024 | 15513 | 0.070 |
Why?
|
Atherosclerosis | 1 | 2023 | 3405 | 0.070 |
Why?
|
Students, Medical | 1 | 2020 | 1938 | 0.070 |
Why?
|
DNA Damage | 2 | 2013 | 2443 | 0.070 |
Why?
|
DNA Replication | 1 | 2013 | 1415 | 0.070 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2024 | 5667 | 0.070 |
Why?
|
Atrial Fibrillation | 1 | 2024 | 5115 | 0.060 |
Why?
|
Physicians | 1 | 2023 | 4583 | 0.060 |
Why?
|
Pandemics | 2 | 2022 | 8663 | 0.060 |
Why?
|
Neoplasms | 1 | 2014 | 22125 | 0.060 |
Why?
|
RNA, Small Interfering | 1 | 2013 | 3409 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3352 | 0.060 |
Why?
|
Aging | 1 | 2022 | 8701 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2024 | 58946 | 0.050 |
Why?
|
Bradycardia | 1 | 2024 | 298 | 0.050 |
Why?
|
Inflammation | 1 | 2022 | 10758 | 0.050 |
Why?
|
Platelet Count | 1 | 2024 | 782 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5427 | 0.050 |
Why?
|
Aged | 6 | 2024 | 169266 | 0.050 |
Why?
|
Internship and Residency | 1 | 2020 | 5879 | 0.040 |
Why?
|
Transplantation, Autologous | 1 | 2024 | 2112 | 0.040 |
Why?
|
Job Satisfaction | 1 | 2023 | 545 | 0.040 |
Why?
|
Gene Expression | 1 | 2012 | 7567 | 0.040 |
Why?
|
DNA-Binding Proteins | 3 | 2024 | 9566 | 0.040 |
Why?
|
Female | 9 | 2024 | 392458 | 0.040 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5318 | 0.040 |
Why?
|
Mice, Nude | 2 | 2016 | 3604 | 0.040 |
Why?
|
Inflammasomes | 1 | 2022 | 525 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8529 | 0.040 |
Why?
|
Interleukin-1beta | 1 | 2022 | 1002 | 0.030 |
Why?
|
DNA-Activated Protein Kinase | 1 | 2016 | 112 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2024 | 20981 | 0.030 |
Why?
|
Uric Acid | 1 | 2022 | 806 | 0.030 |
Why?
|
Male | 6 | 2024 | 360675 | 0.030 |
Why?
|
Carcinoma, Large Cell | 1 | 2016 | 113 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2016 | 3591 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2024 | 4822 | 0.030 |
Why?
|
Research Personnel | 1 | 2020 | 588 | 0.030 |
Why?
|
Tissue Donors | 1 | 2024 | 2334 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2016 | 478 | 0.030 |
Why?
|
Fellowships and Scholarships | 1 | 2022 | 1116 | 0.030 |
Why?
|
Internal Medicine | 1 | 2020 | 1051 | 0.030 |
Why?
|
Drug Synergism | 1 | 2016 | 1756 | 0.030 |
Why?
|
Middle Aged | 5 | 2024 | 220835 | 0.020 |
Why?
|
Faculty, Medical | 1 | 2020 | 1205 | 0.020 |
Why?
|
Risk Factors | 3 | 2024 | 74219 | 0.020 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2012 | 121 | 0.020 |
Why?
|
Thrombosis | 1 | 2024 | 2944 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2024 | 80673 | 0.020 |
Why?
|
Adult | 4 | 2024 | 221083 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 54419 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2012 | 13630 | 0.020 |
Why?
|
Gene Knockout Techniques | 1 | 2012 | 799 | 0.020 |
Why?
|
Signal Transduction | 1 | 2012 | 23415 | 0.020 |
Why?
|
Inpatients | 1 | 2019 | 2545 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2019 | 1846 | 0.020 |
Why?
|
Young Adult | 2 | 2024 | 59199 | 0.020 |
Why?
|
Prevalence | 1 | 2024 | 15717 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9324 | 0.020 |
Why?
|
Incidence | 1 | 2024 | 21357 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10203 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 3268 | 0.020 |
Why?
|
Biomedical Research | 1 | 2020 | 3429 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 2012 | 1984 | 0.010 |
Why?
|
Prognosis | 1 | 2024 | 29672 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2016 | 5781 | 0.010 |
Why?
|
Animals | 3 | 2022 | 168083 | 0.010 |
Why?
|
Mice | 2 | 2022 | 81324 | 0.010 |
Why?
|
Cohort Studies | 1 | 2024 | 41486 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26068 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 2016 | 6340 | 0.010 |
Why?
|
Risk Assessment | 1 | 2019 | 24013 | 0.010 |
Why?
|
DNA | 1 | 2012 | 7189 | 0.010 |
Why?
|
Time Factors | 1 | 2019 | 39953 | 0.010 |
Why?
|
Adolescent | 1 | 2024 | 88271 | 0.010 |
Why?
|
United States | 1 | 2023 | 72337 | 0.010 |
Why?
|
Child | 1 | 2023 | 80134 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2019 | 64670 | 0.010 |
Why?
|